2 results
Approved WMORecruiting
To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.
Approved WMORecruiting
Objective: to provide proof of concept for the inhibition of HBx mediated cccDNA transcription by terbinafine, both as monotherapy and add-on therapy next to tenofovir. Secondary outcomes will be the safety and tolerability of terbinafine in this…